2016 News Releases

Webcast ImageWebcast
Initial Update: RA101495 Phase 2 Program in Paroxysmal Nocturnal Hemoglobinuria (PNH) (Live)
June 27, 2017 at 8:00 a.m. ET
Initial Update: RA101495 Phase 2 Program in Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 27, 2017 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

Read More

Ra Pharmaceuticals to Present Overview of RA101495 and Oral C5 Inhibitor at the International PNH Interest Group Annual Scientific Assembly

Read More

Ra Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Read More

Ra Pharmaceuticals Receives Orphan Drug Designation in the European Union for RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

Read More

Ra Pharmaceuticals Announces Pricing of Initial Public Offering

Read More

Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association

Read More

Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association

Read More

Ra Pharmaceuticals to Present at the Jefferies 2016 Complement Therapeutics Summit

Read More

Ra Pharmaceuticals Appoints Chief Scientific Officer and Expands Board of Directors

Read More

Ra Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference

Read More

Ra Pharmaceuticals Strengthens Senior Management Team

Read More